Alkermes plc. Interest Expense Nonoperating
Alkermes plc. (ALKS) reported Interest Expense Nonoperating of $25.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-07-28
- Alkermes plc. interest expense nonoperating for the quarter ending 2026-06-30 was $25.93M.
- Alkermes plc. interest expense nonoperating for the quarter ending 2026-03-31 was $20.89M.
- Alkermes plc. interest expense nonoperating for the quarter ending 2025-12-31 was $12.28M, a 164.14% increase year-over-year.
- Alkermes plc. interest expense nonoperating for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Alkermes plc. interest expense nonoperating for fiscal 2025 was $12.28M, a 45.62% decline from fiscal 2024.
- Alkermes plc. interest expense nonoperating for fiscal 2024 was $22.58M, a 1.97% decline from fiscal 2023.
- Alkermes plc. interest expense nonoperating for fiscal 2023 was $23.03M, a 76.63% increase from fiscal 2022.
- Alkermes plc. interest expense nonoperating for fiscal 2022 was $13.04M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.93M 10-Q · filed 2026-07-28 | $46.82M 10-Q · filed 2026-07-28 | $59.09M derived: sum of 3 quarters · filed 2026-07-28 | $59.09M derived: sum of 4 quarters · filed 2026-07-28 |
| 2026-03-31 | $20.89M 10-Q · filed 2026-05-05 | $33.17M derived: sum of 2 quarters · filed 2026-05-05 | $33.17M derived: sum of 3 quarters · filed 2026-05-05 | $33.17M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-12-31 | $12.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $12.28M derived: sum of 2 quarters · filed 2026-02-25 | $12.28M derived: sum of 3 quarters · filed 2026-07-28 | $12.28M 10-K · filed 2026-02-25 |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-28 | $0.00 derived: sum of 2 quarters · filed 2026-07-28 | $0.00 10-Q · filed 2025-10-28 | $4.65M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-06-30 | $0.00 10-Q · filed 2026-07-28 | $0.00 10-Q · filed 2026-07-28 | $4.65M derived: sum of 3 quarters · filed 2026-07-28 | $10.65M derived: sum of 4 quarters · filed 2026-07-28 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-05 | $4.65M derived: sum of 2 quarters · filed 2026-05-05 | $10.65M derived: sum of 3 quarters · filed 2026-05-05 | $16.60M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $4.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $10.65M derived: sum of 2 quarters · filed 2026-02-25 | $16.60M derived: sum of 3 quarters · filed 2026-02-25 | $22.58M 10-K · filed 2026-02-25 |
| 2024-09-30 | $6.00M 10-Q · filed 2025-10-28 | $11.95M derived: sum of 2 quarters · filed 2025-10-28 | $17.93M 10-Q · filed 2025-10-28 | $23.98M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $5.95M 10-Q · filed 2025-07-29 | $11.93M 10-Q · filed 2025-07-29 | $17.98M derived: sum of 3 quarters · filed 2026-02-25 | $23.99M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $5.98M 10-Q · filed 2025-05-01 | $12.03M derived: sum of 2 quarters · filed 2026-02-25 | $18.04M derived: sum of 3 quarters · filed 2026-02-25 | |
| 2023-12-31 | $6.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $12.06M derived: sum of 2 quarters · filed 2026-02-25 | $23.03M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $6.01M 10-Q · filed 2024-10-24 | $16.98M 10-Q · filed 2024-10-24 | ||
| 2022-12-31 | $13.04M 10-K · filed 2025-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |